Delisting Danger Passes for Echo Therapeutics
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Echo Therapeutics Inc. regained compliance with the $1 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Philadelphia medical device company is developing Symphony, a needle-free and wireless continuous glucose monitoring system. Dr. Patrick T. Mooney, chairman and CEO of Echo, said the company’s initial target for Symphony system is hospital patients, such as those in critical-care units, who could benefit from glucose monitoring.
Help employers find you! Check out all the jobs and post your resume.
Echo Therapeutics Inc. regained compliance with the $1 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Philadelphia medical device company is developing Symphony, a needle-free and wireless continuous glucose monitoring system. Dr. Patrick T. Mooney, chairman and CEO of Echo, said the company’s initial target for Symphony system is hospital patients, such as those in critical-care units, who could benefit from glucose monitoring.
Help employers find you! Check out all the jobs and post your resume.